← Back to Search

Radiation Therapy

GammaTile for Brain Tumor

N/A
Recruiting
Research Sponsored by GT Medical Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Summary

The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.

Eligible Conditions
  • Brain Tumor
  • Glioblastoma
  • Brain Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival in High Grade Glioma Subjects
Surgical Bed-Recurrence Free Survival in Meningioma Tumor Subjects
Surgical Bed-Recurrence Free Survival in Metastatic Tumor Subjects

Trial Design

1Treatment groups
Experimental Treatment
Group I: GammaTileExperimental Treatment1 Intervention
Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.

Find a Location

Who is running the clinical trial?

GT Medical Technologies, Inc.Lead Sponsor
5 Previous Clinical Trials
1,037 Total Patients Enrolled
Michael A. Garcia, MD, MSStudy DirectorGT Medical Technologies
Lisa Misell, PhD GT Medical TechnologiesStudy DirectorGT Medical Technologies
~303 spots leftby Oct 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top